ZFIN Fish: s1999tTg; sh256Tg

ZFIN ID: ZDB-FISH-150901-21738

ZFIN ID: ZDB-FISH-150901-21738

Fish name:	s1999tTg; sh256Tg
Genotype:	s1999tTg; sh256Tg
Targeting Reagent:	none

HUMAN DISEASE MODELED by s1999tTg; sh256Tg
No data available

GENE EXPRESSION
Gene expression in s1999tTg; sh256Tg

RNA expression

Expressed Gene	Structure	Conditions	Figures
cxcl8a	leukocyte	transection: caudal fin	Fig. 4 from Ogryzko et al., 2014
il1b	leukocyte macrophage	transection: caudal fin	Fig. 1 , Fig. 4 from Ogryzko et al., 2014
ptgs2b	leukocyte	transection: caudal fin	Fig. 4 from Ogryzko et al., 2014

Protein expression No data available

Reporter gene expression No data available

PHENOTYPE
Phenotype in s1999tTg; sh256Tg

Phenotype	Conditions	Figures
leukocyte il1b expression amount, ameliorated	transection: caudal fin, chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor	Fig. 4 from Ogryzko et al., 2014
leukocyte il1b expression amount, ameliorated	transection: caudal fin, chemical treatment by environment: purinergic receptor P2X antagonist	Fig. 4 from Ogryzko et al., 2014
leukocyte ptgs2b expression increased amount, abnormal	transection: caudal fin	Fig. 4 from Ogryzko et al., 2014
leukocyte il1b expression increased amount, abnormal	transection: caudal fin	Fig. 4 from Ogryzko et al., 2014
leukocyte cxcl8a expression increased amount, abnormal	transection: caudal fin	Fig. 4 from Ogryzko et al., 2014
leukocyte cxcl8a expression increased amount, abnormal	transection: caudal fin, chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor	Fig. 4 from Ogryzko et al., 2014
leukocyte ptgs2b expression increased amount, abnormal	transection: caudal fin, chemical treatment by environment: purinergic receptor P2X antagonist	Fig. 4 from Ogryzko et al., 2014
leukocyte ptgs2b expression increased amount, abnormal	transection: caudal fin, chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor	Fig. 4 from Ogryzko et al., 2014
leukocyte cxcl8a expression increased amount, abnormal	transection: caudal fin, chemical treatment by environment: purinergic receptor P2X antagonist	Fig. 4 from Ogryzko et al., 2014
macrophage chemotaxis decreased occurrence, abnormal	transection: caudal fin, chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor	Fig. 2 from Ogryzko et al., 2014
macrophage chemotaxis decreased occurrence, abnormal	transection: caudal fin, chemical treatment by environment: purinergic receptor P2X antagonist	Fig. 2 from Ogryzko et al., 2014

CITATIONS (4)